Renin and angiotensin converting enzyme (ACE) are thought to be specific angiotensin I-and angiotensin IIproducing enzymes, respectively. However, alternative angiotensin II-producing enzymes have been reported in vitro. It has been reported that cathepsin D, like renin, converts angiotensinogen to angiotensin I, although renin generates angiotensin I from angiotensinogen at least 100,000 times faster than cathepsin D. 1 Chymase 2-4 and cathepsin G, 2,5 like ACE, have the ability to convert angiotensin II from angiotensin I, at a similar or faster rate than ACE. Furthermore, cathepsin G, 6 tonin 7 and kallikrein 8 directly convert angiotensinogen to angiotensin II in vitro.
Angiotensin II-forming pathways in human and rat vascular tissues.
Figure 2
HPLC analysis of the degradation of angiotensin I after incubation of the extract (1 mg protein/ml) from human and rat arteries with 4 mM angiotensin I for 30 min.The samples were applied to a reversed phase column (4.6 mm x 250 mm), which was eluted with 20% acetonitrile for 25 min at a flow-rate of 1.0 ml/min, then with a linear gradient of acetonitrile (20-35%) for 5 min and finally with a linear gradient of acetonitrile (35-70%) for 5 min. and the other at 25.2 min ( Figure 2) . These peaks were identified as angiotensin II and angiotensin- (5) (6) (7) (8) (9) (10) respectively. In extracts from human vascular tissue, only 8% of angiotensin II formation was inhibited by lisinopril, but it was 95% inhibited by chymostatin. The other product, angiotensin-(1-9) was inhibited completely by carboxypeptidase inhibition. In extracts from rat vascular tissues, angiotensin II formation was suppressed to 4% by lisinopril, but was not affected by chymostatin. Angiotensin-(5-10) was completely inhibited by chymostatin. These findings suggest that angiotensin-(1-9) formation in humans is generated by carboxypeptidase A 24, 25 and angiotensin-(5-10) in rats is generated by chymase. 2 Therefore, angiotensin II formation is predominantly dependent on chymase in human vascular extract while in extract from rat vascular tissues, angiotensin II formation is dependent only on ACE. Angiotensin I-induced vascular contraction. To clarify the functional role of chymase-dependent angiotensin II formation in vascular tissue, the effects of chymase and ACE inhibitors on the vascular contractile response of angiotensin I were examined. Human and rat arteries contracted in response to angiotensin I. The angiotensin I-induced vascular contractile response reflects the conversion of angiotensin I to angiotensin II. In isolated human vascular tissue, the contractile response was suppressed by up to 30% with the ACE inhibitor lisinopril, and the remaining response was completely suppressed by a combination of lisinopril and chymostatin, a chymase inhibitor, 26 suggesting that the angiotensin I-induced vascular contractile response in isolated human vessels is due to angiotensin II formation dependent on both ACE (30%) and chymase (70%). Conversely, in isolated rat vascular tissue, angiotensin I-induced vascular contraction was completely suppressed by lisinopril alone, suggesting that the conversion of angiotensin I to angiotensin II in rat vascular tissues is dependent on ACE only. The ratios of chymase : ACE dependence of angiotensin I-induced vascular contraction in human, monkey, hamster and dog were about 70% to 30%, 50% to 50%, 35% to 65% and 30% to 70%, respectively ( Figure 3 ). Therefore, it is important to choose monkey, hamster and dog and not rat as animal models to investigate the role of chymasedependent angiotensin II formation.
In vivo experiments
Hypertension. Angiotensin II plays an important role in the regulation of blood pressure. Although it has been thought that angiotensin II is generated by the circulating renin-angiotensin system, renin and ACE activities in plasma were apparently normal or low in the chronic stage of hypertensive rat models, spontaneously hypertensive rats, 27 one-kidney, one clip hypertensive rats 28 and two-kidney and one clip (2K1C) hypertensive rats. 29 We demonstrated that vascular ACE was activated and local production of vascular angiotensin II was increased universally in various hypertensive models during the chronic stage. [27] [28] [29] [30] These findings suggest that the increase of angiotensin II generated by ACE in vascular tissues plays a crucial role in the pathogenesis of hypertension. To clarify the possible roles of the two vascular angiotensin II-forming enzymes, chymase and ACE, in the acute and chronic stages of hypertension, we studied a 2K1C hypertensive model in hamsters. 31 The blood pressure in the 2K1C hamster increased significantly 2 weeks after clipping (acute stage), reached a peak after 4 weeks, and was sustained at the high level until 32 weeks after clipping (chronic stage). Plasma renin activity increased significantly during the acute stage, but returned to the normal level during the chronic stage. In the chronic stage, the vascular ACE activity, but not the chymase activity, increased significantly, and an ACE inhibitor and an angiotensin II type 1 (AT 1 ) receptor antagonist equally lowered the blood pressure during the acute and chronic stage. This finding suggests that vascular chymase is not involved in the pathogenesis of hypertension. Vascular proliferation after balloon injury. Angiotensin II is known to play crucial roles in cell migration and proliferation of vascular tissues. 32, 33 For example, an ACE inhibitor was effective in preventing the proliferation of vascular tissue after balloon injury of vessels in rat. 34, 35 Rat vascular tissue contains only ACE as an angiotensin II-forming enzyme, 26 and these results suggest that vascular angiotensin II formation plays a critical role in tissue proliferation. Based on these reports, a study of ACE inhibitor suppression of vascular restenosis after percutaneous transluminal coronary angioplasty (PTCA) was performed in humans, but the result was negative. 36, 37 Such species differences in the effects of ACE inhibitors on neointimal formation after injury may depend on whether or not a given species possesses angiotensin II-forming chymase in vascular tissue. We demonstrated that in dog, the activities of chymase and ACE in arteries injured by a balloon catheter were increased compared with those in uninjured arteries 1 month after injury; an AT 1 -receptor antagonist was effective in preventing intimal formation of vessels after injury, but an ACE inhibitor was ineffective (Figure 4 ). 38, 39 Restenosis after PTCA was also prevented clinically by an anti-allergic agent, tranilast. 40 Tranilast has been wide-EDITORIAL REVIEW 
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(Including other peptidergic systems)
ly used for the clinical treatment of bronchial asthma, atopic dermatitis and hypertrophic scar and keloid. 41, 42 Although the mechanism by which tranilast prevents restenosis after PTCA is not clear, we have demonstrated that tranilast antagonized angiotensin II-induced contraction in isolated human vascular tissues. 43 Functional blockade of angiotensin II by tranilast may be useful for prevention of vascular hypertrophy in injured vessels. The chymase-dependent angiotensin II formation in human vascular tissue may be closely related to development of neointima formation in vessels injured by a balloon catheter. Vascular proliferation in grafted veins. Stenosis of coronary arteries is commonly treated by PTCA or by surgical therapies such as grafts of arteries or veins. In previous therapeutic studies of stenosis in grafted vessels, an ACE inhibitor was effective in preventing proliferation, in rat but not in baboon grafted vessels. 44 Baboon vascular tissues demonstrate chymase-dependent angiotensin II formation, and the different effects of ACE inhibitors may also depend on species differences in angiotensin II-forming pathways. 45 We investigated the effects of an AT 1 -receptor antagonist and a chymase inhibitor in dog grafted veins. Dogs underwent right common carotid artery bypass grafting with the ipsilaterial external jugular vein. Twenty eight days after the operation, chymase activity in the grafted veins was increased 10-fold over compared with that in the contra lateral veins, and the ACE activity was doubled. The mean intimal area of the grafted veins in the placebo group was regarded as 100%, while the areas in the group treated with the AT 1 antagonist and the chymase inhibitor were reduced to 25.5 and 36.1%, respectively ( Figure 5 ). In this model, we demonstrated for the first time that a chymase inhibitor may prevent vascular proliferation in grafted veins. 46
Summary
In the normal state, vascular ACE regulates local angiotensin II formation and plays a crucial role in the regulation of blood pressure, whereas chymase is stored in secretory granules in mast cells and has no enzymatic effects such as angiotensin II-forming activity. 47 Chymase has a maximal activity immediately upon release into the extracellular matrix in vascular tissues after mast cells have been activated by a strong stimulus such as experienced by catheter-injured and grafted vessels. 48 Therefore, chymase plays an important role in forming local angiotensin II when vascular tissues are injured, and inhibition of chymase may be useful for preventing vascular proliferation in grafted vessels and after PTCA ( Figure 6 ).
Figure 6
Proposed pathways responsible for angiotensin II formation in vascular tissue. In normal state,ACE in endothelial cells converts angiotensin I to angiotensin II, whereas chymase in mast cells in adventitia is an inactive-type and has no enzymatic effects including angiotensin II-forming ability. In the injured vessels in the grafted veins and PTCA, the endothelial cells is driven away, whereas the mast cells in the adventitia are activated by the stimulus and chymase forms angiotensin II from angiotensin I.
Figure 5
Effects of an angiotensin II type 1 receptor antagonist, L-158,809 (10 mg/kg day, p.o.), and a chymase inhibitor, Suc-Val-Pro-Phe p (POh)2 (10 µM during operation), on the intimal area in the grafted veins 28 days after operation.
